The North America travel vaccines market size reached USD 2.1 Billion in 2025. Looking forward, the analyst expects the market to reach USD 3.5 Billion by 2034, exhibiting a growth rate (CAGR) of 5.33% during 2026-2034.
Vaccines are defined as biological preparations that protect the human body against severe and potentially deadly diseases. They generally consist of an agent made from the surface protein, toxins, weakened or killed forms of the disease-causing microorganisms. Vaccination enables the body to produce antibodies, which provide a shield in case the person is exposed to the disease. For travel vaccines, also known as travel immunizations, travelers are vaccinated 4 to 6 weeks before the journey. These can be differentiated between recommended and required vaccines. Wherein, required vaccines are essential for the individual to get before entering a country. However, recommended vaccines are those which the traveler may need because of a potential infection threat in the country or a part of that country. Some of the most common vaccine-preventable, travel-related diseases include influenza, meningitis, rabies, tick-borne encephalitis, polio, diphtheria, tetanus, pertussis, etc.
North America travel vaccines market is currently being driven by several factors. One of the key factors driving the demand of travel vaccines is their ability to prevent the risk of disease epidemic. Moreover, vaccination provides immunity to individuals, travelling to places where there is a high risk of exposure or contracting a specific disease. As a result, governments in the region have mandated vaccination before visiting certain destinations with a high prevalence of infectious diseases. Other factors driving the demand of travel vaccines in the region include rising number of travelers, government initiatives, technological advancements such as combination vaccines and needle free techniques, etc.
Vaccines are defined as biological preparations that protect the human body against severe and potentially deadly diseases. They generally consist of an agent made from the surface protein, toxins, weakened or killed forms of the disease-causing microorganisms. Vaccination enables the body to produce antibodies, which provide a shield in case the person is exposed to the disease. For travel vaccines, also known as travel immunizations, travelers are vaccinated 4 to 6 weeks before the journey. These can be differentiated between recommended and required vaccines. Wherein, required vaccines are essential for the individual to get before entering a country. However, recommended vaccines are those which the traveler may need because of a potential infection threat in the country or a part of that country. Some of the most common vaccine-preventable, travel-related diseases include influenza, meningitis, rabies, tick-borne encephalitis, polio, diphtheria, tetanus, pertussis, etc.
North America travel vaccines market is currently being driven by several factors. One of the key factors driving the demand of travel vaccines is their ability to prevent the risk of disease epidemic. Moreover, vaccination provides immunity to individuals, travelling to places where there is a high risk of exposure or contracting a specific disease. As a result, governments in the region have mandated vaccination before visiting certain destinations with a high prevalence of infectious diseases. Other factors driving the demand of travel vaccines in the region include rising number of travelers, government initiatives, technological advancements such as combination vaccines and needle free techniques, etc.
Key Market Segmentation:
The report provides an analysis of the key trends in each segment of the North America travel vaccines market report, along with forecasts at the regional and country levels from 2026-2034. Our report has categorized the market based on composition and disease.- Key Regions Analysed
o United States
o Canada
o Mexico
- Analysis for Each Country
- Market by Composition
o Mono Vaccines
o Combination Vaccines
- Market by Disease
o Hepatitis A
o DPT
o Yellow Fever
o Typhoid
o Hepatitis B
o Measles and Mumps
o Rabies
o Meningococcal
o Varicella
o Japanese Encephalitis
o Others
- Value Chain Analysis
- Key Drivers and Challenges
- Porters Five Forces Analysis
- PESTEL Analysis
- Government Regulations
- Competitive Landscape
o Competitive Structure
o Key Player Profiles
Key Questions Answered in This Report
1.What was the size of the North America travel vaccines market in 2025?
2.What is the expected growth rate of the North America travel vaccines market during 2026-2034?
3.What are the key factors driving the North America travel vaccines market?
4.What has been the impact of COVID-19 on the North America travel vaccines market?
5.What is the breakup of the North America travel vaccines market based on the composition?
6.What is the breakup of the North America travel vaccines market based on the disease?
7.What are the key regions in the North America travel vaccines market?
Table of Contents
1 Preface3 Executive Summary13 Price Analysis
2 Scope and Methodology
4 Introduction
5 Global Travel Vaccines Market
6 North America Travel Vaccines Market
7 North America Travel Vaccines Market: Breakup by Composition
8 North America Travel Vaccines Market: Breakup by Disease
9 North America Travel Vaccines Market: Breakup by Country
10 SWOT Analysis
11 Value Chain Analysis
12 Porter’s Five Forces Analysis
14 Competitive Landscape
List Figures
List of Tables
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 140 |
| Published | February 2026 |
| Forecast Period | 2025 - 2034 |
| Estimated Market Value ( USD | $ 2.1 Billion |
| Forecasted Market Value ( USD | $ 3.5 Billion |
| Compound Annual Growth Rate | 5.8% |
| Regions Covered | North America |
